Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi Biologics (Cayman)'s Total Liabilities for the quarter that ended in Dec. 2025 was MXN27,245 Mil.
WuXi Biologics (Cayman)'s quarterly Total Liabilities
declined
from Dec. 2024 (MXN32,941.58 Mil) to Jun. 2025 (MXN29,821.68 Mil) and
declined
from Jun. 2025 (MXN29,821.68 Mil) to Dec. 2025 (MXN27,245.26 Mil).
WuXi Biologics (Cayman)'s annual Total Liabilities
increased
from Dec. 2023 (MXN29,853.50 Mil) to Dec. 2024 (MXN32,941.58 Mil) but then
declined
from Dec. 2024 (MXN32,941.58 Mil) to Dec. 2025 (MXN27,245.26 Mil).
WuXi Biologics (Cayman) Total Liabilities Related Terms
WuXi Biologics (Cayman) Total Liabilities Historical Data
* Premium members only.
The historical data trend for WuXi Biologics (Cayman)'s Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
WuXi Biologics (Cayman)'s Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of MXN27,245 Mil mean?
WuXi Biologics (Cayman) (MEX:2269N) has a Total Liabilities of MXN27,245 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for WuXi Biologics (Cayman) and its competitors.
Is WuXi Biologics (Cayman)'s Total Liabilities too high?
WuXi Biologics (Cayman)'s current Total Liabilities is MXN27,245 Mil. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Total Liabilities compare to VRTX and REGN?
WuXi Biologics (Cayman)'s Total Liabilities of MXN27,245 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current Total Liabilities is MXN27,245 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
WuXi Biologics (Cayman) (MEX:2269N) has a current Total Liabilities of MXN27,245 Mil. The stock's GF Value™ is MXN54.50, compared to a current price of MXN62.53 — trading 14.7% above its estimated fair value. The current Total Liabilities is MXN27,245 Mil. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For WuXi Biologics (Cayman) (MEX:2269N), the current Total Liabilities is MXN27,245 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (MEX:2269N) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be overvalued.
The current stock price of MXN62.53 is trading 14.7% above its estimated GF Value™ of MXN54.50.
Key valuation signals for MEX:2269N:
Total Liabilities: MXN27,245 Mil
GF Value™: MXN54.50 vs. price of MXN62.53 (14.7% above fair value)
No single metric tells the full story. See the MEX:2269N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score
Get the complete analysis for MEX:2269N
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:2269N has been successfully added to your 
